BioAge Labs (BIOA) Cost of Revenue (2024 - 2026)

BioAge Labs has disclosed Cost of Revenue across 3 years of filings, most recently posting $13.1 million for Q1 2026.

• Cost of Revenue for Q1 2026 came in at $13.1 million, up 183.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $58.0 million (up 56.02% YoY), and the FY2025 annual result was $49.4 million, up 33.17% from the prior year.
• Cost of Revenue came in at $13.1 million for Q1 2026 at BioAge Labs, down from $18.6 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $18.6 million in Q4 2025 to a low of $4.6 million in Q1 2024.
• The 3-year median for Cost of Revenue is $13.1 million (2026), against an average of $11.1 million.
• Peak annual rise in Cost of Revenue reached 198.06% in 2025, while the deepest fall reached 15.41% in 2025.
• BioAge Labs' Cost of Revenue stood at $13.4 million in 2024, then surged by 39.35% to $18.6 million in 2025, then declined by 29.41% to $13.1 million in 2026.
• The last three Cost of Revenue figures came in at $13.1 million (Q1 2026), $18.6 million (Q4 2025), and $12.2 million (Q3 2025), per Business Quant data.